Background

When treating migraine attacks as they happen, finding a medication that works is only half the battle—patients also need a treatment they can consistently rely on without disruptive side effects.

A landmark retrospective cohort study published in Cephalalgia provides the first real-world observational data comparing how long patients actually stay on two newer acute migraine therapies: rimegepant (a gepant) and lasmiditan (a ditan). The results were clear: patients taking rimegepant were significantly more likely to continue their treatment over a 12-month period.

Both rimegepant and lasmiditan represent advanced, targeted mechanisms of action designed for patients who cannot tolerate or do not respond to traditional triptans. While clinical trials show both are effective at stopping a migraine, clinical trials don’t always capture everyday patient behavior.

This study looked at treatment persistence for acute migraines—whether a patient fills a repeat prescription within a year—which serves as a key indicator of overall real-world treatment satisfaction, effectiveness, and tolerability.

How the Study Was Done

Researchers analyzed de-identified US insurance claims from the massive MarketScan databases, identifying adults who newly initiated treatment with either rimegepant or lasmiditan between March 2020 and December 2022.

• The Study Size: The analysis included 16,603 rimegepant users and 716 lasmiditan users.
• The Criteria: To ensure accuracy, the study focused strictly on patients using these medications for acute attacks (defined by a standard index fill of 8 tablets). All participants had a confirmed migraine diagnosis and 12 months of continuous insurance enrollment both before and after their first prescription.
• Statistical Rigor: Advanced weighting (IPTW) was used to perfectly balance baseline differences between the two groups, including age, complex comorbidities, and prior medication histories.

Study Results

The study found a substantial, statistically significant advantage in favor of rimegepant across the board.

• Higher Overall Persistence: In the primary analysis, patients in the rimegepant cohort demonstrated vastly superior treatment persistence compared to the lasmiditan cohort. 77.1% of rimegepant users filled at least one repeat prescription within 12 months, compared to just 47.2% of lasmiditan users. Statistically, rimegepant users had 3.79 times higher odds of remaining persistent with their treatment.
• Consistency Across Lasmiditan Dosages: This trend held strong regardless of the specific strength of lasmiditan a patient was originally prescribed. Rimegepant showed a clear persistence advantage against both the 50 mg dose (OR 5.05) and the 100 mg dose (OR 3.33) of lasmiditan.
• Success in Chronic Migraine Patients: Managing chronic migraine (15 or more headache days per month) is notoriously complex. Yet, in this severe subgroup, rimegepant users maintained an exceptionally high persistence rate of 78.98%, compared to just 49.36% for lasmiditan, resulting in 3.89 times higher odds of persistence.
• Overcoming a History of Controlled Substances: The researchers also looked at a subgroup of patients with a history of using controlled substances (like opioids or butalbital) or central nervous system (CNS)-active nausea medications for their headaches. Because lasmiditan is a Schedule V controlled substance with known sedative properties, past behaviors could theoretically influence how patients use it. However, rimegepant consistently came out on top, showing significantly higher persistence rates regardless of whether patients had a history of repeated controlled substance use.

Why the Large Gap in Persistence?

The study authors note that real-world treatment persistence is heavily driven by a patient’s total experience, balancing speed of relief against side effects that hinder their ability to function. The massive gap between these two drugs likely comes down to everyday lifestyle barriers:

• The 8-Hour Driving Restriction: Lasmiditan carries a strict FDA label restriction requiring patients to avoid driving or operating machinery for at least 8 hours after every single dose due to risks of incoordination. This frequently forces patients to delay taking their medication until they are safely home, violating the gold standard clinical rule of treating a migraine immediately at onset. Rimegepant carries no such driving restriction.
• Adverse Event Profiles: Lasmiditan is associated with central nervous system side effects like dizziness, sedation, and fatigue in more than 5% of users. In contrast, rimegepant’s most common side effect is mild nausea, occurring in only 2% of users, allowing patients to treat their pain and seamlessly return to their daily routines.

Conclusion

This real-world data confirms that rimegepant provides a highly favorable, convenient, and sustainable treatment experience for patients. By avoiding the strict driving limitations and heavy sedative side effects of lasmiditan, rimegepant allows individuals to manage their acute migraine attacks effectively while maintaining their long-term treatment routine.